179 related articles for article (PubMed ID: 29894516)
1. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
Fonseca-Alves CE; Kobayashi PE; Rivera Calderón LG; Felisbino SL; Rinaldi JC; Drigo SA; Rogatto SR; Laufer-Amorim R
PLoS One; 2018; 13(6):e0199173. PubMed ID: 29894516
[TBL] [Abstract][Full Text] [Related]
2. Different Growth Patterns of Canine Prostatic Carcinoma Suggests Different Models of Tumor-Initiating Cells.
Akter SH; Lean FZ; Lu J; Grieco V; Palmieri C
Vet Pathol; 2015 Nov; 52(6):1027-33. PubMed ID: 25755134
[TBL] [Abstract][Full Text] [Related]
3. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.
Tan HL; Haffner MC; Esopi DM; Vaghasia AM; Giannico GA; Ross HM; Ghosh S; Hicks JL; Zheng Q; Sangoi AR; Yegnasubramanian S; Osunkoya AO; De Marzo AM; Epstein JI; Lotan TL
Mod Pathol; 2015 Mar; 28(3):446-56. PubMed ID: 25216229
[TBL] [Abstract][Full Text] [Related]
4. Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.
de Brot S; Lothion-Roy J; Grau-Roma L; White E; Guscetti F; Rubin MA; Mongan NP
Vet Comp Oncol; 2022 Mar; 20(1):38-49. PubMed ID: 33963663
[TBL] [Abstract][Full Text] [Related]
5. Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
Wu M; Ingram L; Tolosa EJ; Vera RE; Li Q; Kim S; Ma Y; Spyropoulos DD; Beharry Z; Huang J; Fernandez-Zapico ME; Cai H
J Biol Chem; 2016 Dec; 291(49):25749-25760. PubMed ID: 27760825
[TBL] [Abstract][Full Text] [Related]
6. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis.
Fonseca-Alves CE; Rodrigues MM; de Moura VM; Rogatto SR; Laufer-Amorim R
Microsc Res Tech; 2013 Dec; 76(12):1250-6. PubMed ID: 24030851
[TBL] [Abstract][Full Text] [Related]
7. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
8. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of NKX3.1 and C-MYC expression in canine prostatic cancer.
Fonseca-Alves CE; Kobayashi PE; Laufer-Amorim R
Res Vet Sci; 2018 Jun; 118():365-370. PubMed ID: 29665565
[TBL] [Abstract][Full Text] [Related]
10. Alterations in PTEN, MDM2, TP53 and AR protein and gene expression are associated with canine prostate carcinogenesis.
Rivera-Calderón LG; Fonseca-Alves CE; Kobayashi PE; Carvalho M; Drigo SA; de Oliveira Vasconcelos R; Laufer-Amorim R
Res Vet Sci; 2016 Jun; 106():56-61. PubMed ID: 27234536
[TBL] [Abstract][Full Text] [Related]
11. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
12. Investigation of c-KIT and Ki67 expression in normal, preneoplastic and neoplastic canine prostate.
Fonseca-Alves CE; Kobayashi PE; Palmieri C; Laufer-Amorim R
BMC Vet Res; 2017 Dec; 13(1):380. PubMed ID: 29207991
[TBL] [Abstract][Full Text] [Related]
13. Nectin-4 and p63 immunohistochemical expression in canine prostate tumourigenesis.
Della Salda L; Massimini M; Romanucci M; Palmieri C; Perillo A; Grieco V; Malatesta D; Spinillo MA; Passantino G; Dondi F; Benazzi C
Vet Comp Oncol; 2019 Sep; 17(3):298-307. PubMed ID: 30767361
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry in diagnostic surgical pathology of the prostate.
Hameed O; Humphrey PA
Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
[TBL] [Abstract][Full Text] [Related]
15. Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma.
Lin X; Shi Q; Yang XJ
Hum Pathol; 2022 Dec; 130():36-46. PubMed ID: 36244466
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of heat shock proteins, p63 and androgen receptor in benign prostatic hyperplasia and prostatic carcinoma in the dog.
Romanucci M; Frattone L; Ciccarelli A; Bongiovanni L; Malatesta D; Benazzi C; Brachelente C; Della Salda L
Vet Comp Oncol; 2016 Dec; 14(4):337-349. PubMed ID: 25059752
[TBL] [Abstract][Full Text] [Related]
17. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression.
Ferronika P; Triningsih FX; Ghozali A; Moeljono A; Rahmayanti S; Shadrina AN; Naim AE; Wudexi I; Arnurisa AM; Nanwani ST; Harijadi A
Asian Pac J Cancer Prev; 2012; 13(5):1943-8. PubMed ID: 22901151
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
19. Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells?
Sailer V; Stephan C; Wernert N; Perner S; Jung K; Dietel M; Kristiansen G
Histopathology; 2013 Jul; 63(1):50-6. PubMed ID: 23668398
[TBL] [Abstract][Full Text] [Related]
20. Survivin and Sox9: Potential Stem Cell Markers in Canine Normal, Hyperplastic, and Neoplastic Canine Prostate.
Bongiovanni L; Caposano F; Romanucci M; Grieco V; Malatesta D; Brachelente C; Massimini M; Benazzi C; Thomas RE; Salda LD
Vet Pathol; 2019 Mar; 56(2):200-207. PubMed ID: 30131013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
